Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis
Launched by SECOND AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Dec 13, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • moderate-to-severe UC
- • Treated with Vedolizumab
- Exclusion Criteria:
- • had recent supplementation of vitD3
- • pregnant
- • had cognitive/developmental disorders that affected their ability to complete the study procedures
- • had medical illness or therapies potentially affecting bone, nutrition or growth status
- • unknown or untested baseline serum 25(OH)D level
Trial Officials
Xia shenglong, Master
Principal Investigator
Second Affiliated Hospital of Wenzhou Medical University
About Second Affiliated Hospital Of Wenzhou Medical University
The Second Affiliated Hospital of Wenzhou Medical University is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent teaching hospital, it integrates clinical practice with innovative research and education, fostering a collaborative environment for healthcare professionals. The hospital is equipped with state-of-the-art facilities and a diverse range of specialized departments, enabling it to conduct comprehensive clinical trials across various medical fields. Its mission is to enhance healthcare outcomes through rigorous scientific inquiry and to contribute to the global body of medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wenzhou, Zhejiang, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials